Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

por Hutchings, Martin, Morschhauser, Franck, Iacoboni, Gloria, Carlo-Stella, Carmelo, Offner, Fritz C., Sureda, Anna, Salles, Gilles, Martínez-Lopez, Joaquín, Crump, Michael, Thomas, Denise N., Morcos, Peter N., Ferlini, Cristiano, Bröske, Ann-Marie E., Belousov, Anton, Bacac, Marina, Dimier, Natalie, Carlile, David J., Lundberg, Linda, Perez-Callejo, David, Umaña, Pablo, Moore, Tom, Weisser, Martin, Dickinson, Michael J.
Publicado 2021

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

por Dickinson, Michael J., Barba, Pere, Jäger, Ulrich, Shah, Nirav N., Blaise, Didier, Briones, Javier, Shune, Leyla, Boissel, Nicolas, Bondanza, Attilio, Mariconti, Luisa, Marchal, Anne-Laure, Quinn, David S., Yang, Jennifer, Price, Andrew, Sohoni, Akash, Treanor, Louise M., Orlando, Elena J., Mataraza, Jennifer, Davis, Jaclyn, Lu, Darlene, Zhu, Xu, Engels, Boris, Moutouh-de Parseval, Laure, Brogdon, Jennifer L., Moschetta, Michele, Flinn, Ian W.
Publicado 2023